Key result
Adding serum GSDMD to NT-proBNP and EF boosts heart failure diagnostic accuracy to ~0.99 AUC.
Why the study?
The value of serum Gasdermin D (GSDMD) as a novel biomarker for early diagnosis and disease progression of heart failure was not established.
Does serum GSDMD provide diagnostic value for heart failure compared to NT-ProBNP and EF?
Observational (n=318)
No
Does serum GSDMD provide diagnostic value for heart failure compared to NT-ProBNP and EF?
Effect estimate: AUC 0.819 (95% CI 0.775-0.863)
p-value: p=<0.001
Serum GSDMD is a novel sensitive biomarker that shows potential for the early diagnosis and assessment of disease progression in heart failure.
Serum GSDMD shows diagnostic promise in HF; hypothesis-generating and should not yet alter clinical practice.
Objective: This study analyzes the value of serum Gasdermin D (GSDMD) as a novel biomarker for the early diagnosis and disease progression of heart failure. Methods: We conducted a retrospective analysis of clinical data and laboratory results to compare the GSDMD levels among the heart failure group, other cardiac disease group, and healthy control group. We investigates the correlation between GD and other indicators, as well as the independent risk factors for heart failure. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic value of serum GSDMD, N-terminal pro-B-type natriuretic peptide (NT-ProBNP), ejection fraction (EF) in patients. Results: There were statistically significant differences in serum GSDMD, EF and other laboratory tests among the three groups (P<0.05). Among heart failure patients with different cardiac function classifications, the serum levels of NT-ProBNP, GSDMD increased with the increase in cardiac function classification. Serum GSDMD was correlated with all indicators (P<0.05) in subjects. Serum GSDMD and NT-ProBNP were independent risk factors while EF was an independent protective factor for heart failure. The AUCs of serum GSDMD, NT ProBNP, and EF for diagnosing heart failure were 0.819, 0.970, and 0.831, respectively, while the AUC of their combined diagnosis of heart failure was 0.986. Conclusion: This study suggests that Serum GSDMD, as a novel sensitive biomarker, has the potential for early diagnosis and disease progression assessment of heart failure.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) conducted an observational in Heart failure (n=318). Serum GSDMD vs. Healthy controls and other cardiac diseases was evaluated on Diagnosis of heart failure (AUC 0.819, 95% CI 0.775-0.863, p=<0.001). Serum GSDMD demonstrated significant diagnostic value for heart failure with an AUC of 0.819, which increased to 0.986 when combined with NT-ProBNP and ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: